VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
VolitionRx (NYSE American: VNRX) has scheduled its Second Quarter 2026 Earnings and Business Update conference call for Friday, August 14, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VolitionRx (NYSE American: VNRX) has scheduled its Second Quarter 2026 Earnings and Business Update conference call for Friday, August 14, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time). The call will cover financial and operating results, important Q2 events, subsequent developments, and upcoming milestones.
The call will be hosted by Group Chief Marketing & Communications Officer Louise Batchelor, President and Group CEO Cameron Reynolds, and Group CFO Terig Hughes. Investors can join via regional dial-in numbers using Conference ID 13762190, or access a live audio webcast and replay available until August 28, 2026.
Details
News Market Reaction – VNRX
On Aug 12, the first trading day after this news, VNRX closed 7.65% below the previous close. Argus tracked a peak move of +9.1% during that session. Argus tracked a trough of -17.9% from its starting point during tracking. Our momentum scanner recorded 28 alerts for this stock that day. Relative volume reached 134.0x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 12 session.
Historical Context
-
Peer-reviewed Capture-Seq publication and reported cancer-detection results
-
Nu.Q NETs evidence and commercialization discussions with diagnostic companies
-
Nu.Q Cancer Assay data indicated prognostic value in lung cancer
-
Sysmex collaboration targeted optimization of the Nu.Q NETs H3.1 assay
-
Public offering priced at $1.55 per share with accompanying warrants
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to take place on Friday, August 14 at 8:30 a.m.
Event: VolitionRx Limited Second Quarter 2026 Earnings and Business Update Conference Call
Date: Friday, August 14, 2026
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13762190
Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the second quarter 2026, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until August 28, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-second-quarter-2026-earnings-conference-call-and-business-update-302848674.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.